Elite Pharmaceuticals Inc (Elite Pharmaceuticals) is a speciality pharmaceutical company primarily engaged in the development and manufacture of oral, controlled-release products, and the manufacture of generic pharmaceuticals. The company focuses on developing generic versions of controlled-release drug products with high barriers to entry. Elite Pharmaceuticals operates under Current Good Manufacturing Practice (cGMP) and is a United States Drug Enforcement Agency (DEA) registered facility for research, development, and manufacturing. The company serves the pharmaceutical industry, particularly in the generic drug market.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D focuses on developing proprietary abuse deterrent technologies and abuse deterrent opioid products, alongside differentiated niche generics, especially solid oral dosage forms that are difficult to formulate, such as extended release medicines. The company also evaluates contract development, contract manufacturing, and in licensing opportunities to broaden and strengthen its portfolio. R&D is primarily conducted through its wholly owned subsidiary, Elite Laboratories, Inc., which is responsible for research, development, licensing, manufacturing, and sales of generic oral pharmaceuticals, including controlled release products. Activities are centred at the Northvale Facility. In FY2025, the company spent US$7.9 million on its R&D activities, which was 9.4% of its revenue and grew 15.6% YoY.